Regeneron Pharmaceuticals Reports Promising Phase 3 Trial Results for Libtayo in High-Risk Cutaneous Squamous Cell Carcinoma

Regeneron's Libtayo (cemiplimab) demonstrated a statistically significant 68% reduction in the risk of disease recurrence or death in patients with high-risk cutaneous squamous cell carcinoma (CSCC) following surgery, as shown in the Phase 3 C-POST trial. The study, presented at ASCO and published in NEJM, also highlighted significant reductions in locoregional and distant recurrences compared to placebo. Regulatory applications have been submitted in the U.S. and EU for Libtayo's use in the adjuvant treatment of CSCC, potentially establishing it as a new standard of care, despite some reported adverse events.

Analysis

Regeneron Pharmaceuticals (REGN) has announced highly promising results from the Phase 3 C-POST trial for Libtayo (cemiplimab) in treating high-risk cutaneous squamous cell carcinoma (CSCC) post-surgery, demonstrating a 68% reduction in the risk of disease recurrence or death (p<0.0001) compared to placebo. These findings, presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the New England Journal of Medicine, also showed a median disease-free survival (DFS) not reached for Libtayo-treated patients versus 49 months for placebo, with two-year DFS rates of 87% for Libtayo and 64% for placebo. Libtayo also achieved significant reductions in locoregional (80%) and distant (65%) recurrence risks, and an emerging overall survival benefit trend (HR: 0.78). Regulatory applications for this adjuvant CSCC indication have been submitted in the U.S. and EU, positioning Libtayo to potentially become a new standard of care. While efficacy was consistent regardless of PD-L1 expression, the safety profile showed 91% of Libtayo patients experiencing any grade adverse events (AEs) versus 89% for placebo, with Grade ≥3 AEs occurring in 24% of Libtayo patients compared to 14% in the placebo arm, and treatment discontinuations due to AEs at 10% for Libtayo versus 2% for placebo; deaths due to AEs were two in each arm. Wall Street analysts reflect a positive outlook with three recent buy-equivalent ratings and a median price target of $850.0. Conversely, institutional activity in Q1 2025 showed more investors decreasing (771) than increasing (649) positions, including substantial sales by firms like JPMorgan Chase and Capital World Investors, although Two Sigma Advisers and Goldman Sachs made significant additions. Congressional trading data over the past six months also indicates a predominance of sales (8 sales vs. 1 purchase).

Key Decisions for Investors

• Investors should consider the robust clinical efficacy data for Libtayo and upcoming U.S. and EU regulatory decisions as significant potential catalysts for Regeneron, potentially expanding Libtayo's market share.
• It is prudent to weigh the positive clinical outcomes and bullish analyst sentiment against the observed net institutional selling by some large funds and recent divestment trends among congressional members before making investment decisions.
• Monitor closely the regulatory approval process, subsequent market penetration, and real-world safety data of Libtayo in the adjuvant CSCC setting, as these will be critical determinants of its commercial success and impact on Regeneron's valuation.